Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and improved financial performance
ROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update highlighting the Company’s transformation and growth initiatives under the leadership of its new Chief Executive Officer, Eric Hines.
Since joining Milestone Scientific two months ago, Mr. Hines has conducted a comprehensive review of the Company’s operations and implemented a series of strategic actions designed to accelerate growth, strengthen its competitive position, and improve operating efficiency. Actions within the dental segment include expanding the Company’s North American sales programs and increasing the focus on direct sales opportunities; streamlining and expanding omnichannel digital marketing to increase brand awareness; and securing new international registrations for the STA® Single Tooth Anesthesia System. The Company plans to utilize a similar strategy for its medical segment, including a guided relaunch of CompuFlo®. In addition, the Company is investing in specialized market analysis and reimbursement strategies to maximize the commercial potential of the Company’s CompuFlo® technology in healthcare settings. Lastly, the Company is instituting broad-based reductions in operating expenses across the organization.
“We have taken strong, decisive steps over the past two months to align Milestone Scientific for the next phase of growth,” stated Eric Hines, Chief Executive Officer of Milestone Scientific. “Through a top-to-bottom analysis of the business, we have identified significant opportunities for improvement and begun executing initiatives to capture them. Notably, during the third quarter, we reduced our operating expenses by approximately 20% compared to the same period in 2024, while achieving modest revenue growth and seeing an uptick in recurring revenue from the CompuFlo disposables, even before fully implementing our new sales and marketing initiatives. We are also observing strong interest in CompuFlo internationally. Although we have been relatively quiet publicly, there is a significant amount of activity taking place behind the scenes that we believe will strengthen both our medical and dental segments and enhance the Company’s financial performance.”
Hines continued, “We remain committed to advancing our innovative technology, expanding our market presence, and executing on our pipeline of new products and partnerships. The steps we are taking now – from strengthening our sales infrastructure to optimizing our operations – provide a strong foundation for sustained growth and profitability. I could not be more encouraged by the outlook for the business and look forward to sharing updates on our progress.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient, and increase the overall patient comfort and safety. The Company leverages its proprietary DPS Dynamic Pressure Sensing Technology® platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetics. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
